Clee Medical is proud to announce that it has been named a winner of the »venture» 2025 startup competition, Switzerland’s leading entrepreneurship award. Selected from a record 396 applicants, this recognition highlights Clee Medical’s pioneering work in developing next-generation neurotechnology for real-time intraoperative brain imaging and AI-guided navigation.
The »venture» competition, founded by ETH Zurich, McKinsey & Company, Knecht Holding, Innosuisse, and other key partners, celebrates Switzerland’s most promising early-stage companies. The 2025 jury recognized Clee Medical for its unique combination of ultra-high-resolution imaging, AI-based tissue identification, and its potential to transform the way neurosurgeons access and treat the brain.
We are deeply honored to receive this recognition from >>venture>>,said Matt Lapinski, CEO of Clee Medical.This award is a testament to our team’s relentless pursuit of innovation and our vision to enable safer, more precise, and more effective neurosurgery. We are grateful to our partners, mentors, and the Swiss innovation ecosystem for their continued support.
Building on this achievement, Clee Medical will continue to advance its Neuro Access platform toward clinical deployment. The company’s mission is to empower surgeons with instantaneous, high-fidelity imaging and intelligent guidance to improve patient outcomes, increase the efficiency of neurosurgery, and expand access to advanced neurotherapies worldwide.
This milestone reinforces Clee Medical’s position among Switzerland’s most promising deep-tech startups and underscores its commitment to driving the future of minimally invasive neurosurgery through innovation, precision, and collaboration.